| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
MRGPRX4 modulator-2 selectively targets MRGPRX4, a receptor predominantly expressed in sensory neurons and associated with itch perception and cholestatic pruritus. The compound possesses antagonist activity against MRGPRX4 with an IC50 < 100 nM, blocking receptor activation and downstream signaling.
|
|---|---|
| ln Vitro |
MRGPRX4 modulator-2 demonstrates potent antagonist activity against MRGPRX4 with an IC50 < 100 nM. By modulating MRGPRX4 activity, it offers a novel approach to managing chronic itch conditions, especially those linked to liver disease and opioid-induced pruritus. It can be used for researching autoimmune diseases.
|
| ln Vivo |
Dedicated in vivo efficacy studies for MRGPRX4 modulator-2 are not extensively documented in standard profiles. As a modulator of a receptor involved in itch perception, it is hypothesized to reduce scratching behavior and pruritus in animal models of cholestasis or chronic itch. Detailed in vivo data are not publicly available.
|
| Enzyme Assay |
The antagonist activity of MRGPRX4 modulator-2 is measured in a cell-based functional assay. Cells expressing recombinant MRGPRX4 are incubated with a known agonist (e.g., bile acids) and varying concentrations of the modulator. Receptor activation is measured using a calcium flux assay or a reporter gene readout. The IC50 < 100 nM is calculated.
|
| Cell Assay |
Cells expressing MRGPRX4 (e.g., HEK293 cells transfected with MRGPRX4) are cultured and treated with MRGPRX4 modulator-2. After pre-incubation, cells are stimulated with a known MRGPRX4 agonist. Intracellular calcium levels are measured using a fluorescent calcium indicator (e.g., Fluo-4). Inhibition of the calcium response confirms antagonist activity.
|
| Animal Protocol |
Dedicated in vivo protocols for MRGPRX4 modulator-2 are not well-documented. A standard protocol would involve a mouse model of cholestatic pruritus (e.g., bile duct ligation or DDC diet-induced) or a mouse model of acute itch. The compound would be administered systemically, and scratching behavior would be quantified.
|
| ADME/Pharmacokinetics |
Detailed PK parameters for MRGPRX4 modulator-2 are not extensively documented. The compound has a molecular weight of 348.68 g/mol and is soluble in DMSO (>50 mg/mL), facilitating formulation for in vivo studies. Comprehensive ADME data are not publicly reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for MRGPRX4 modulator-2 are not available in standard profiles. As a research chemical, comprehensive toxicology studies have not been performed. Standard laboratory safety precautions apply.
|
| References | |
| Additional Infomation |
MRGPRX4 modulator-2 is a potent tool for studying MRGPRX4 biology. This receptor is a promising therapeutic target for chronic pruritus, particularly cholestatic pruritus associated with liver disease. The compound is not an approved drug.
|
| Molecular Formula |
C15H9CLF4O3
|
|---|---|
| Molecular Weight |
348.676777601242
|
| Exact Mass |
348.017
|
| CAS # |
2492595-24-9
|
| PubChem CID |
155145968
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
418
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(O)(=O)C1=CC=CC(COC2=CC=C(C(F)(F)F)C=C2Cl)=C1F
|
| InChi Key |
TWOXPNAILYKJPT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H9ClF4O3/c16-11-6-9(15(18,19)20)4-5-12(11)23-7-8-2-1-3-10(13(8)17)14(21)22/h1-6H,7H2,(H,21,22)
|
| Chemical Name |
3-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-2-fluorobenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~143.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8680 mL | 14.3398 mL | 28.6796 mL | |
| 5 mM | 0.5736 mL | 2.8680 mL | 5.7359 mL | |
| 10 mM | 0.2868 mL | 1.4340 mL | 2.8680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
